Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.84
-0.27 (-2.43%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $8.97M in the quarter ending June 30, 2026, a decrease of -61.33%. This brings the company's total for the last twelve months to $28.73M, down -83.86% year-over-year. In the year 2025, Monte Rosa Therapeutics had annual revenue of $123.67M with 63.54% growth. That makes Monte Rosa Therapeutics the 31,604th largest company in the world by revenue and 4,169th in the United States.
Revenue (ttm)
$28.73M
Revenue Growth
-83.86%
P/S Ratio
32.19
Revenue / Employee
$166,052
Employees
173
Market Cap
924.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 123.67M | 48.05M | 63.54% |
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| MannKind | 393.63M |
| Rigel Pharmaceuticals | 276.79M |
| City Therapeutics | 14.34M |
| Aktis Oncology | 10.06M |
| Odyssey Therapeutics | 99.00K |
GLUE News
- 12 days ago - Monte Rosa Therapeutics assumed with a Buy at UBS - TheFly
- 21 days ago - Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Monte Rosa Therapeutics Transcript: Study result - Transcripts
- 23 days ago - Monte Rosa Therapeutics Press release: Study result - Filings
- 23 days ago - Monte Rosa Therapeutics Slides: Study result - Filings
- 23 days ago - Monte Rosa announces data from GFORCE-1, plans for Phase 2 program of MRT-8102 - TheFly
- 23 days ago - Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk - GlobeNewsWire
- 23 days ago - Monte Rosa Therapeutics initiated with a Buy at H.C. Wainwright - TheFly